肥胖肺炎患者静脉使用利奈唑胺的药代动力学评估
结果显示标准剂量下PTA低,且随体重增加而降低、随年龄增加而升高;<65岁患者对MIC 1-4 mg/L的MRSA靶值达成率近零至60%。
要点
- 肥胖肺炎患者标准剂量利奈唑胺对MRSA的PKPD靶值达成率低。
- 体重和年龄显著影响利奈唑胺清除率,PTA随体重增加而降低、随年龄增加而升高。
- <65岁肥胖患者标准剂量对MIC 1-4 mg/L MRSA的PTA近零至60%。
核心结论
- 肥胖肺炎患者使用标准剂量利奈唑胺可能对MRSA靶值达成不足。
- 体重尤其是年龄是给予利奈唑胺治疗MRSA感染时需考虑的重要特征。
研究设计与样本
- 采用群体药代动力学建模描述PK变异并筛选影响因素,蒙特卡洛模拟评估PTA和靶值达成时间。
主要发现
- 二室模型伴线性消除充分描述数据,体重和年龄对利奈唑胺清除率均有显著影响。
- 模拟显示达到PKPD靶值的概率低,PTA随体重增加而降低、随年龄增加而升高。
- 标准剂量下<65岁肥胖肺炎患者对MIC 1-4 mg/L MRSA的PTA近零至60%。
关键数值与推荐
- 利奈唑胺剂量为600 mg静脉q12h。
- 评估MRSA MIC范围为1-4 mg/L。
- <65岁患者标准剂量下PTA近零至60%。
临床怎么用
- 肥胖肺炎患者使用利奈唑胺治疗MRSA时需关注体重和年龄对靶值达成的影响。
- 标准剂量可能不足,应考虑个体化给药或治疗药物监测。
局限性
- 研究仅评估静脉给药3天的PK,长期用药数据未涉及。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Altered linezolid pharmacokinetics (PK) in obese individuals has been hypothesized in previous studies. However, specific dosing recommendations for this population are still lacking. The main goal of this study was to evaluate PK/pharmacodynamic (PKPD) target attainment when using a 600 mg intravenous q12h linezolid dose against MRSA in obese patients with pneumonia. METHODS: Fifteen obese pneumonia patients with a confirmed or suspected MRSA involvement treated with 600 mg of intravenous linezolid q12h were studied for 3 days. Population PK modelling was used to characterize the PK variability and to screen for influential patient characteristics. Monte Carlo simulations were carried out to investigate the PTA and time to target attainment for linezolid dosing against MRSA. RESULTS: A two-compartment model with linear elimination adequately described the data. Body weight and age both have a significant effect on linezolid clearance. Simulations demonstrate that the probability of attaining PKPD targets is low. Moreover, the PTA decreases with weight, and increases with age. Standard linezolid dosing in obese pneumonia patients with MRSA (MICs of 1-4 mg/L) leads to unacceptably low (near zero to 60%) PTA for patients <65 years old. CONCLUSIONS: Standard linezolid dosing is likely to provide insufficient target attainment against MRSA in obese patients. Body weight and especially age are important characteristics to be considered when administering linezolid to treat MRSA infections.
引用
- Xie F, Mantzarlis K, Malliotakis P, et al. Pharmacokinetic evaluation of linezolid administered intravenously in obese patients with pneumonia. J Antimicrob Chemother. 2019. PMID: 30535122. doi:10.1093/jac/dky500
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。